Apellis Pharmaceuticals, Inc. (APLS) financial statements (2020 and earlier)

Company profile

Business Address 6400 WESTWIND WAY
CRESTWOOD, KY 40014
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments434176176
Cash and cash equivalents434176176
Prepaid expense15245
Other current assets200
Other undisclosed current assets 11
Total current assets:451202182
Noncurrent Assets
Finance lease, right-of-use asset13
Property, plant and equipment2  
Other noncurrent assets010
Total noncurrent assets:1510
TOTAL ASSETS:466204182
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities42157
Accounts payable12104
Accrued liabilities3053
Debt22 
Total current liabilities:45177
Noncurrent Liabilities
Long-term debt and lease obligation111920
Long-term debt, excluding current maturities 1920
Finance lease, liability11
Liabilities, other than long-term debt077
Due to related parties 77
Other liabilities0  
Other undisclosed noncurrent liabilities27100
Total noncurrent liabilities:2822627
Total liabilities:3274333
Stockholders' equity
Stockholders' equity attributable to parent140161149
Common stock000
Additional paid in capital608438298
Accumulated other comprehensive loss(0)(0) 
Accumulated deficit(468)(277)(149)
Total stockholders' equity:140161149
TOTAL LIABILITIES AND EQUITY:466204182

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Operating expenses(219)(128)(51)
Operating loss:(219)(128)(51)
Nonoperating income730
Investment income, nonoperating43 
Other nonoperating income (expense)(0)(0)0
Interest and debt expense(2)  
Loss before gain (loss) on sale of properties:(214)(125)(51)
Other undisclosed net loss(4)(2) 
Net loss:(218)(128)(51)
Other undisclosed net loss attributable to parent(10) (0)
Net loss available to common stockholders, diluted:(228)(128)(51)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(218)(128)(51)
Comprehensive loss:(218)(128)(51)
Other undisclosed comprehensive loss, net of tax, attributable to parent(11)(0) 
Comprehensive loss, net of tax, attributable to parent:(228)(128)(51)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: